Welcome to the Australian Arthritis and Autoimmune Biobank Collaborative – A3BC
One third of Australians suffer from arthritis, autoimmune or other musculoskeletal diseases, affecting adults, children and toddlers. These diseases cost Australia over $50 billion per year, account for the greatest disability, and further impact the community through substantial out-of-pocket expenses and reduced employment.
The Australian Arthritis and Autoimmune Biobank Collaborative (A3BC) is a national network of state-of-the-art biobanking, data collection/linkage and big data analytics/machine-learning for enabling and translating research discovery. It integrates a broad range of ‘omic’ (genomic, microbiomic etc), patient-reported (demographics, treatment, quality of life, diet etc), medical and administrative health data from people with arthritis and autoimmune disorders across Australia. The A3BC seeks to:
- Establish an open-access, best-practice national biobank network to collect, process and store a broad range of biospecimens. The A3BC will link, enhance and expand existing biobanks in the musculoskeletal field to improve capacity and capability.
- Integrate this biobank network with the Australian Rheumatology Association Database (ARAD) to link biospecimen ‘omic’ data to ARAD’s patient-reported data. ARAD already has data from >4000 people with inflammatory arthritis and will be expanded/ upgraded as part of the A3BC.
- Integrate this biobank and patient-reported data to a range of other datasets, including Commonwealth data (i.e. MBS, PBS), electronic medical records in each state, and cancer/death registries. Data integration will occur through existing ARAD and new linkage approvals.
- Apply big data analytics/machine-learning to automatically mine integrated data for potential associations of patient and population significance. From the laboratory to clinic, cutting-edge A3BC systems will revolutionise research/health data capture, integration, analysis and sharing.
- Enable pioneering research in precision and preventive medicine for inflammatory arthritis. The provision of critical infrastructure and access to samples, data and integration/analytics support for multidisciplinary research – to facilitate a new era in research innovation and discovery.
- Enable the translation of research discovery into inflammatory arthritis healthcare. The development of new data/knowledge sharing pathways – to narrow the gap between research and evidence-based medicine and give the right care, to the right patient, at the right time.
Please view our video below for an overview of the A3BC vision: